Stockreport

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema [Yahoo! Finance]

EyePoint, Inc.  (EYPT) 
Last eyepoint, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF EyePoint, Inc. – Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU i [Read more]